Studies
| Study First Submitted Date | 2020-02-07 |
| Study First Posted Date | 2020-02-11 |
| Last Update Posted Date | 2020-07-07 |
| Verification Month Year | July 2020 |
| Verification Date | 2020-07-31 |
| Last Update Posted Date | 2020-07-07 |
Browse Interventions
| Sequence: | 95729260 | Sequence: | 95729261 |
| Mesh Term | Daratumumab | Mesh Term | Antineoplastic Agents |
| Downcase Mesh Term | daratumumab | Downcase Mesh Term | antineoplastic agents |
| Mesh Type | mesh-list | Mesh Type | mesh-ancestor |
Id Information
| Sequence: | 40028945 | Sequence: | 40028946 |
| Id Source | org_study_id | Id Source | secondary_id |
| Id Value | CR108780 | Id Value | 54767414MMY4031 |
| Id Type | Other Identifier | ||
| Id Type Description | Janssen Research & Development, LLC | ||
Interventions
| Sequence: | 52317615 |
| Intervention Type | Drug |
| Name | Daratumumab |
| Description | Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection. |
Sponsors
| Sequence: | 48164172 |
| Agency Class | INDUSTRY |
| Lead Or Collaborator | lead |
| Name | Janssen Research & Development, LLC |
Overall Officials
| Sequence: | 29190133 |
| Role | Study Director |
| Name | Janssen Research & Development, LLC Clinical Trial |
| Affiliation | Janssen Research & Development, LLC |
Eligibilities
| Sequence: | 30667983 |
| Minimum Age | N/A |
| Maximum Age | N/A |
| Criteria | Inclusion Criteria: – Exclusion Criteria: – |
| Adult | True |
| Child | True |
| Older Adult | True |
Calculated Values
| Sequence: | 254292713 |
| Registered In Calendar Year | 2020 |
| Were Results Reported | False |
| Has Single Facility | False |
Responsible Parties
| Sequence: | 28781290 |
| Responsible Party Type | Sponsor |